Acute glycaemic effects of co-trimoxazole at prophylactic dose in healthy adults

被引:1
作者
Kenteu, Bernold [1 ]
Noubiap, Jean Jacques N. [2 ,3 ]
Etoa, Martine Claude [1 ,4 ]
Azabji-Kenfack, Marcel [5 ]
Dehayem, Mesmin [4 ]
Sobngwi, Eugene [1 ,4 ,6 ,7 ,8 ]
机构
[1] Univ Yaounde I, Fac Med & Biomed Sci, Dept Internal Med & Specialties, Yaounde, Cameroon
[2] Groote Schuur Hosp, Dept Med, Cape Town, South Africa
[3] Univ Cape Town, Cape Town, South Africa
[4] Yaounde Cent Hosp, Diabet & Metab Dis Unit, Natl Obes Ctr, Yaounde, Cameroon
[5] Univ Yaounde I, Fac Med & Biomed Sci, Dept Physiol Sci & Biochem, Yaounde, Cameroon
[6] Univ Yaounde I, Biotechnol Ctr, Yaounde, Cameroon
[7] Univ Yaounde I, Yaounde Cent Hosp, Natl Obes Ctr, Yaounde, Cameroon
[8] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon
来源
BMC ENDOCRINE DISORDERS | 2016年 / 16卷
关键词
Co-trimoxazole; Glycaemia; Adults; TRIMETHOPRIM-SULFAMETHOXAZOLE; INDUCED HYPOGLYCEMIA; INFECTION;
D O I
10.1186/s12902-016-0142-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cases of severe hypoglycaemia were reported in HIV/AIDS patients receiving high dose of the sulfonylurea co-trimoxazole for opportunistic infections. Whether co-trimoxazole at prophylactic dose would induce similar side effects is unknown. We aimed to investigate the acute effects of co-trimoxazole at prophylactic dose on glucose metabolism in healthy adults. Methods: We enrolled 20 healthy volunteers (15 males and 5 females) aged 23.0 (SD 2.0) years, with mean BMI of 22.3 (SD 3.6) Kg/m(2) with normal glucose tolerance, hepatic and renal function. We performed a 75-g oral glucose tolerance test (OGTT) with and without concomitant oral co-trimoxazole administered 60 min before the test. Blood glucose response was measured using a capillary test at baseline and at 30, 60, 90, 120 and 180 min following oral glucose load on the two occasions. C-peptide response was also measured. Absolute values of blood glucose and C-peptide with and without co-trimoxazole were compared using the Wilcoxon test. Results: During the OGTT without co-trimoxazole (control) vs. the OGTT with co-trimoxazole (test), the glycaemia varied from 4.83 (SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44 (SD 0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs. 7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94) mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78 (SD 1.00) mmol/l vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351) and 4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180 (P = 0.747). The ratio of area under the glycaemia curve during the control and test investigation was 96.7 %, thus a 3.3 decreased glycaemic response (p = 0.062). A decrease of glycaemia by more than 10 % occurred in 6/20 participants at T30, 7/20 participants at T60 and 1/20 participant at T30 and T60. None of the volunteers experienced co-trimoxazole-induced hypoglycaemia. At the same time, the C-peptide response during the control vs. the test investigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8 (SD 42.5) pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6) pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and 1049.8 (SD 503.1) pmol/l vs. 1041.63 (SD 824.21) pmol/l at T180 (P = 0.893). Conclusion: Ninety minutes after its administration, co-trimoxazole induced a significant reduction of the early glycaemic response to oral glucose in parallel with a 27-% increase in insulin secretory response. Co-trimoxazole induced within 120 min a more than 10-% blood glucose reduction in 2/3 of participants. However none of the volunteers experienced hypoglycaemia.
引用
收藏
页数:5
相关论文
共 9 条
[1]   SULFONAMIDE-INDUCED HYPOGLYCEMIA IN CHRONIC-RENAL-FAILURE [J].
AREM, R ;
GARBER, AJ ;
FIELD, JB .
ARCHIVES OF INTERNAL MEDICINE, 1983, 143 (04) :827-829
[2]   Cotrimoxazole prophylaxis and antiretroviral therapy: an observational cohort study in China [J].
Cheng, Wei ;
Wu, Yasong ;
Wen, Yi ;
Ma, Ye ;
Zhao, Decai ;
Dou, Zhihui ;
Zhang, Weiwei ;
Bulterys, Marc ;
Zhang, Fujie .
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2015, 93 (03) :152-160
[3]   Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection [J].
Hekimsoy, Z ;
Biberoglu, S ;
Comlekci, A ;
Tarhan, O ;
Mermut, C ;
Biberoglu, K .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1997, 136 (03) :304-306
[4]   Considerations when prescribing trimethoprim-sulfamethoxazole [J].
Ho, Joanne M. -W. ;
Juurlink, David N. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (16) :1851-1858
[5]   Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda [J].
Mermin, J ;
Lule, J ;
Ekwaru, JP ;
Malamba, S ;
Downing, R ;
Ransom, R ;
Kaharuza, F ;
Culver, D ;
Kizito, F ;
Bunnell, R ;
Kigozi, A ;
Nakanjako, D ;
Wafula, W ;
Quick, R .
LANCET, 2004, 364 (9443) :1428-1434
[6]  
Nunnari G, 2010, EUR REV MED PHARMACO, V14, P1015
[7]   Anti-Infectives and the Risk of Severe Hypoglycemia in Users of Glipizide or Glyburide [J].
Schelleman, H. ;
Bilker, W. B. ;
Brensinger, C. M. ;
Wan, F. ;
Hennessy, S. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) :214-222
[8]   GLYCEMIC THRESHOLDS FOR ACTIVATION OF GLUCOSE COUNTERREGULATORY SYSTEMS ARE HIGHER THAN THE THRESHOLD FOR SYMPTOMS [J].
SCHWARTZ, NS ;
CLUTTER, WE ;
SHAH, SD ;
CRYER, PE .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (03) :777-781
[9]   Severe and protracted hypoglycaemia associated with co-trimoxazole use [J].
Strevel, EL ;
Kuper, A ;
Gold, WL .
LANCET INFECTIOUS DISEASES, 2006, 6 (03) :178-182